Physician profile
Adalbert Pilip
NPI 1548424039
$8,672.11
in general payments reported to CMS, 2019-2025
48 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $700 · 2021: $69.14 · 2022: $1,398 · 2023: $1,707 · 2024: $2,375 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,599.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,852.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $925.44 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $778.05 | 2019-2025 | |
| Abbott Laboratories | $627.09 | 2019-2025 | Freestyle Libre 3, Jot Dx, Optis |
| Pfizer INC. | $439.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $423.03 | 2019-2024 | Verquvo, Steglatro |
| Novo Nordisk INC | $352.93 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Cvrx, INC. | $330.89 | 2024 | Barostim Neo System |
| Amgen INC. | $315.19 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.05 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $255.68 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $241.41 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Medtronic Vascular, INC. | $141.43 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $132.98 | 2019-2023 | Livalo |
| Hikma Pharmaceuticals USA | $125.63 | 2022-2025 | Ryaltris |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2022 | |
| Exact Sciences Corporation | $120.67 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $118.41 | 2019-2022 | |
| Heartflow, INC. | $104.10 | 2022-2025 | Ffrct |
| Daiichi Sankyo INC. | $82.04 | 2023-2024 | Injectafer |
| Optos, INC. | $72.17 | 2020 | |
| Avvisto Therapeutics, LLC | $68.32 | 2024 | Cycloset |
| Corcept Therapeutics | $52.46 | 2024 | Korlym |
| Lundbeck LLC | $47.65 | 2025 | Vyepti |
| Seqirus USA INC | $44.81 | 2022-2024 | Fluad, Flucelvax |
| Regeneron Healthcare Solutions, INC. | $44.14 | 2019-2022 | |
| Boston Scientific Corporation | $42.58 | 2022 | |
| Genentech USA, INC. | $35.18 | 2019-2020 | |
| Medicomp INC | $32.03 | 2023 | Telepatch Cardiac Monitor |
| Sanofi-Aventis U.S. LLC | $31.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.88 | 2019-2020 | |
| Baxter Healthcare | $28.19 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Abbvie INC. | $28.14 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $27.27 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $25.17 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $24.26 | 2022 | |
| Celgene Corporation | $23.91 | 2025 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $23.89 | 2022 | |
| Irhythm Technologies, INC. | $23.56 | 2023 | Zio Xt Patch |
| Dexcom, INC. | $22.77 | 2024 | Dexcom G6 Transmitter |
| Neuronetics, INC. | $22.11 | 2020 | |
| Astellas Pharma US INC | $21.43 | 2020 | |
| Shield Therapeutics INC | $18.60 | 2023 | Accrufer |
| Tactile Systems Technology INC | $18.45 | 2025 | Flexitouch Plus, Nimbl |
| Vivus LLC | $17.96 | 2024 | Qsymia |
| Esperion Therapeutics, INC. | $17.00 | 2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $15.89 | 2022 | |
| Currax Pharmaceuticals LLC | $14.89 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adalbert Pilip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.